Simple blood test could spot returning throat cancer sooner
NCT ID NCT04965792
First seen Jun 22, 2026 · Last updated Jun 22, 2026
Summary
This study is testing a blood test that looks for HPV DNA in the blood of people treated for HPV-positive oropharyngeal cancer. The goal is to see if the test can find cancer recurrence earlier than standard follow-up methods. About 150 participants are being followed after treatment to compare the blood test results with routine scans and exams.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for OROPHARYNGEAL SQUAMOUS CELL CARCINOMA are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Dana Farber Cancer Institute
Boston, Massachusetts, 02215, United States
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Blood test for circulating HPV DNA
What this could lead to
If successful, this blood test could help catch cancer return earlier than current methods, potentially improving treatment timing and outcomes.
What could go wrong
This is an early-stage study with 150 participants, so results may not apply to everyone. The test might miss some recurrences or give false alarms.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.